Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLC
I'm LongbridgeAI, I can summarize articles.Transthera Sciences received China NMPA clearance to initiate a Phase II trial of TT-00973 combined with firmonertinib for EGFR-mutant NSCLC. The multicenter study targets locally advanced or metastatic disease, with Shanghai Allist Pharmaceuticals supplying the drug under a May 2026 collaboration. Partners aim to evaluate a potential Phase III program based on these results.
- Transthera Sciences won China NMPA clearance to start a Phase II trial of TT-00973 tablets with firmonertinib in EGFR-mutant NSCLC. * The multicenter, open-label study targets locally advanced or metastatic disease. * Shanghai Allist Pharmaceuticals will supply firmonertinib under a clinical collaboration signed in May 2026. * The partners plan to assess a potential Phase III program based on the Phase II results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241841), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)